| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |